ClinicalTrials.gg
Not yet recruitingNCT05906524Updated Jan 10, 2024

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

A Phase 1/2 interventional study of KD6001 and Tislelizumab in Advanced HCC and Other Solid Tumors, sponsored by Shanghai Kanda Biotechnology Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-10.

Sponsored by Shanghai Kanda Biotechnology Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
85
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase 1b/2, open label study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of KD6001 in combination with Tislelizumab ± Bevacizumab in patients with Advanced HCC and Other Solid Tumors.

02

Conditions studied

  • Advanced HCC
  • Other Solid Tumors
03

In context

Lead sponsor

Shanghai Kanda Biotechnology Co., Ltd. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Being voluntary to sign the form.
  2. Male or female, aged ≥ 18 years.
  3. Patients whose estimated survival time is more than 3 months.
  4. (ECOG) performance status score 0 or 1.
  5. At least one is used as the target lesion according to the Version 1.1(RECIST V1.1).
  6. or cytologically confirmed advanced solid tumors. Have a current liver function meeting Class A in patients with HCC.

    Part A: Advanced solid tumors. PartB/C: HCC.

  7. Patients will agree to provide tumor tissue samples.
  8. The results of laboratory examination during the screening period suggest that the subjects have good organ function.
  9. Male subjects with reproductive ability or female subjects with the possibility of pregnancy use effective methods.
  10. Good compliance and follow-up.

Main Exclusion Criteria:

  1. History of other than the disease under study within 5 years prior to screening,except those malignancies that are expected to be cured after treatment.
  2. Systematic treatment with antitumor drugs within 4 weeks prior to the start of this study.
  3. Prior treatment with antibody.
  4. Adverse events caused by prior treatment did not recovered to v5.0 grade 1 and below.
  5. Subjects with or .
  6. Subjects with an active, known or suspected disease.
  7. Subjects with acute or chronic active or .
  8. Has histological or cytological diagnosis of fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma.
  9. Subjects suffers from severe cardiovascular and cerebrovascular diseases. History or evidence of bleeding diathesis or significant coagulopathy at risk of bleeding.
  10. Subjects with an active infection requiring systemic treatment.
  11. Known history of testing positive for (HIV).
  12. Subjects known to have active tuberculosis (TB).
  13. Pregnant or breastfeeding females.
  14. Known to be allergic to KD6001, tislelizumab, bevacizumab or its components.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    Phase 1:KD6001+Tislelizumab

    KD6001 combined with Tislelizumab in patients with solid tumors(hepatocellular carcinoma, esophageal squamous cell carcinoma, MSI-H or dMMR solid tumors are preferentially included)

    Drug: KD6001 · Drug: Tislelizumab

  • Experimental
    Phase 2:KD6001+Tislelizumab±Bevacizumab

    KD6001 combined with Tislelizumab±Bevacizumab in patients with advanced HCC

    Drug: KD6001 · Drug: Tislelizumab · Drug: Bevacizumab

Interventions

  • DrugKD6001

    KD6001 will be administered intravenously.

  • Tislelizumab will be administered intravenously.

  • Bevacizumab will be administered intravenously.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose Limiting Toxicities (DLTs)

    DLTs will be assessed during the dose-escalation phase and are defined as the following treatment-related adverse events occurring within a total of 21 days after the first trial administration.

    Time frame: Up to Day 21

  2. The incidence and safety profile of participants with adverse events (AEs), serious adverse events(SAE), and immune-related adverse event(irAE)

    Evaluate the adverse events (AE) according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 (NCI CTCAE 5.0).

    Time frame: Baseline to study completion up to 2 years

Secondary outcomes

  1. The antitumor activity of KD6001 in combination with Tislelizumab ± Bevacizumab measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

    Number of participants with response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.

    Time frame: Baseline to study completion up to 2 years

  2. Maximum Plasma Concentration [Cmax]

    The PK profile of KD6001 in combination with Tislelizumab ± Bevacizumab.

    Time frame: Baseline to study completion up to 2 years

  3. Time to reach maximum serum concentration (Tmax)

    The PK profile of KD6001 in combination with Tislelizumab ± Bevacizumab.

    Time frame: Baseline to study completion up to 2 years

  4. Half-life (T1/2)

    The PK profile of KD6001 in combination with Tislelizumab ± Bevacizumab.

    Time frame: Baseline to study completion up to 2 years

  5. Area under blood concentration-time curve(AUC0-T and AUC0-∞)

    The PK profile of KD6001 in combination with Tislelizumab ± Bevacizumab.

    Time frame: Baseline to study completion up to 2 years

  6. Apparent volume of distribution (Vd)

    The PK profile of KD6001 in combination with Tislelizumab ± Bevacizumab.

    Time frame: Baseline to study completion up to 2 years

  7. The immunogenicity of KD6001 in combination with Tislelizumab ± Bevacizumab

    Including the incidence of ADA positive. For ADA positive patients, the incidence of neutralizing antibody (Nab) will be analyzed.

    Time frame: Baseline to study completion up to 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2024; primary completion for Apr 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2023
First posted
Jun 18, 2023
StartEst.
Apr 15, 2024
Primary completionEst.
Apr 30, 2025
CompletionEst.
Dec 31, 2025
Last update
Jan 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05906524
Lead sponsor
Shanghai Kanda Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Apr 15, 2024 (estimated)
Primary completion
Apr 30, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jan 10, 2024

Study contacts

Chi Zhang
Contact
zhangchi@kandatech.cn
+8615800854907

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-CTLA-4 Monoclonal Antibody KD6001 · Tislelizumab

Start the discussion